taxim o 200 mg tablets film-coated tablet
alkem laboratories 167/1 mahatma gandhi udyog nagar dabhel daman-396 - cefixime trihydrate usp - film-coated tablet - cefixime trihydrate usp 200 mg - beta-lactamantibacterials: third-generation
taxim o ds 50mg/5ml powder for oral solution
alkem laboratories village thana baddi tehsil nalagarh solan - cefixime trihydrate usp - powder for oral solution - cefixime trihydrate usp 50mg/5ml - beta-lactamantibacterials: third-generation
cefixime powder, for suspension
belcher pharmaceuticals,llc - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - to reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. in the absence of such data,local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months of age or older with the following infections when caused by susceptible isolates of the designated bacteria: uncomplicated urinary tract infections caused by escherichia coli and proteus mirabilis otitis media caused by haemophilus influenzae, moraxella catarrhalis, and streptococcus pyogenes. (efficacy for streptococcus py
cef-3 ds capsule
cefixime trihydrate - capsule - cefixime 400 mg/capsule - cefixime
suprax- cefixime tablet, chewable
lupin pharma - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - cefixime anhydrous 100 mg - to reduce the development of drug resistant bacteria and maintain the effectiveness of suprax (cefixime) chewable tablets and other antibacterial drugs, suprax (cefixime) chewable tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. suprax (cefixime) chewable tablets are indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: uncomplicated urinary tract infections caused by escherichia coli and proteus mirabilis . otitis media caused by haemophilus influenzae (beta-lactamase positive and negative strains), moraxella (branhamella) catarrhalis , (most of which are beta-lactamase positive) and s. pyogene
inoxime 100 ds (cefixime for oral suspension) syrup
innocia lifesciences private ltd 12, balaji nagar, ambattur, chennai - 53, - cefixime usp (as trihydrate) - syrup - 100mg/5ml - cefixime
cefichew 200mg tablets chewable
srs pharmaceuticals pvt. ltd. - cefixime (cefixime trihydrate) - tablets chewable - 200mg
cefichew 400mg tablets chewable
srs pharmaceuticals pvt. ltd. - cefixime (cefixime trihydrate) - tablets chewable - 400mg
cefazim-200 tablets film-coated
zim laboratories ltd. - cefixime (cefixime trihydrate) - tablets film-coated - 200mg
cefdia film-coated tablet
İlko İlaç sanayi ve ticaret a. Ş., turkey İlko İlaç san. tic. a.s. veysel karani mah. - cefixime trihydrate - film-coated tablet - 447.63 mg cefixime trihydrate equivalent to 400 - beta-lactamantibacterials: third-generation